Private demand for cholera vaccines in Hue, Vietnam

Value in Health

Volumn 11, Issue 1, 2008, Pages 119-128

  Kim, Dohyeong ^a   Canh, Do G ^b   Poulos, Christine ^c   Thoa, Le T K ^d   Cook, Joe ^a   Hoa, Nguyen T ^e   Nyamete, Andrew ^f   Thuy, Dang T D ^e   Deen, Jacqueline ^f   Clemens, John ^f   Thiem, Vu D ^b   Anh, Dang D ^b   Whittington, Dale ^a,g  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

^c RTI INTERNATIONAL   (United States)

^d Medical College   (Viet Nam)

^e Preventive Medicine Center   (Viet Nam)

^f International Vaccine Institute   (South Korea)

^g University of North Carolina at Chapel Hill   (United States)

Author keywords

Cholera; Contingent valuation method; Vaccine demand; Willingness to pay

Indexed keywords

CHOLERA VACCINE;

ADULT; ARTICLE; CHOLERA; CONTROLLED STUDY; DRUG COST; ECONOMIC ASPECT; FEMALE; HUMAN; MALE; MEDICAL INFORMATION; PRIORITY JOURNAL; VACCINATION; VIET NAM;

EID: 38549133361     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00220.x     Document Type: Article

References (27)

1. World Health Organization (WHO). Cholera, 2005. Wkly Epidemiol Rec 2006 81 : 297 308.
2. World Health Organization (WHO) Global Task Force on Cholera Control. Cholera vaccines: a new public health tool? Report of a WHO meeting, Geneva, Switzerland, December 10-11, 2002. WHO/CDS/CPE/ZFK/2004.
3. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986 2 : 124 7.
4. Clemens JD, Sack DA, Harris JR, et al. Field trials of cholera vaccines in Bangladesh: results from a three-year follow-up. Lancet 1990 335 : 270 3.
5. Sanchez JL, Vasquez B, Beque R, et al. Protective efficacy of the oral whole cell recombinant B subunit cholera vaccine in Peruvian military recruits. Lancet 1994 344 : 1273 6.
6. National Institute of Hygiene and Epidemiology. Thua Thien Province Statistics Yearbook: Regular Report. Hanoi, Vietnam : Statistics Department of Communicable Disease, 2002.
7. Trach DD. The problem of cholera vaccination in Viet Nam. In : Sack DA, Freij L, eds. Prospects for Public Health Benefits in Developing Countries from New Vaccines Against Enteric Infections. Stockholm : SAREC Documentation, 1990.
8. Thiem VD, Hossain MM, Son ND, et al. Coverage and costs of a mass immunization of an oral cholera vaccine in Vietnam. J Health Popul Nutr 2003 21 : 304 8.
9. Carson RT. Contingent valuation: a user's guide. Environ Sci Technol 2000 34 : 1413 18.
10. Carson RT, Flores NE, Meade N. Contingent valuation: controversies and evidence. Environ Resour Econ 2001 19 : 173 210.
11. Whittington D. Administering contingent valuation surveys in developing countries. World Dev 1998 26 : 21 30.
12. Whittington D. Improving the performance of contingent valuation studies in developing countries. Environ Resour Econ 2002 22 : 323 67.
13. Whittington D, Pinheiro A, Cropper M. The economic benefits of malaria prevention: a contingent valuation study in Marracuene, Mozambique. J Health Popul Dev Coun 2003.
14. Cropper M, Haile M, Lampietti J, et al. The demand for a malaria vaccine: evidence from Ethiopia. J Dev Econ 2004 55 : 303 18.
15. Whittington D, Matsui-Santana O, Freiberger J, et al. Private demand for an HIV/AIDS vaccine: evidence from Guadalajara, Mexico. Vaccine 2002 20 : 2585 91.
16. Suraratdecha C, Ainsworth M, Tangcharoensathien V, et al. Private demand for an HIV/AIDS vaccine in Thailand. Health Policy 2005 71 : 271 87.
17. Canh DG, Whittington D, Thoa LTK, et al. Household demand for typhoid fever vaccines in Hue, Vietnam: implications for immunization programs. Health Policy Plan 2006 21 : 241 55.
18. Naficy A, Rao MR, Paguet C, et al. Treatment and vaccination strategies to control cholera in Sub-Saharan refugee settings. JAMA 1998 279 : 521 5.
19. Sack D. When should cholera vaccines be used in cholera-endemic areas? J Health Popul Nutr 2003 24 : 299 303.
20. Cookson ST, Stamboulian D, Demonte J, et al. A cost-benefit analysis of programmatic use of CVD 103Hg-R live oral cholera vaccine in a high-risk population. Int J Epid 1997 26 : 212 19.
21. Kristrom B. Spike models in contingent valuation. Am J Agri Econ 1997 79 : 1013 23.
22. Hanemann WM, Kristrom B. Preference uncertainty, optimal designs and spikes. In : Johansson PO, Kristrom B, Maler KG, eds. Current Issues in Environmental Economics. Manchester, U.K. : Manchester University Press, 1995.
23. Haab T, McConnell K. Valuing Environmental and Natural Resources: The Econometrics of Non-Market Valuation. Cheltenham, UK : Edward Elgar, 2002.
24. Shiell A, Gold L. If the price is right: vagueness and values clarification in contingent valuation. Health Econ 2003 12 : 909 19.
25. Cookson R. Willingness to pay methods in health care: a skeptical view. Health Econ 2003 12 : 891 4.
26. Ali M, Emch M, Seidlein L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005 366 : 44 9.
27. Cook J, Whittington D, Johnson FR, et al. Reliability of stated preferences for vaccine with time to think. Econ Inquiry 2007 45 : 100 14.